Second Genome Stock
Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.
Sign up today and learn more about Second Genome Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Second Genome Stock
Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.
Investors
Advanced Technology Ventures
Funding History
| August 2011 | $5.0M |
|---|---|
| June 2013 | $6.5M |
| April 2016 | $43.0M |
| July 2016 | $8.4M |
Management
Chief Scientific Officer
Karim Dabbagh
Co-Founder & SVP, Platform Technologies
Janet A. Warrington
Senior Director, Corporate Development
Nadir Mahmood
Bioinformatics Scientist
Cheryl-Emiliane Chow
SVP Corporate Development
Mohan Iyer
CEO & President
Glenn Nedwin
Co-Founder & Head of Bioinformatics
Todd DeSantis
Sr VP Research & Development
Peter S. DiStefano
Press
prnewswire - Jan, 19 2022
Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officerbiospace - Aug, 6 2021
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkersxconomy - Oct, 16 2019
Second Genome’s McClure Joins Aligos as Chief Medical Officerprnewswire - Apr, 4 2019
Global Human Microbiome Markets, 2024 - Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics Hold Substantial Market Shareprnewswire - Mar, 31 2019
Second Genome Expands Development of CNS Platform to Validate Microbial Products as Therapeutics for Autism Spectrum Disorderfree-press-release - Feb, 21 2019
Agreements, Partnerships & Collaboration were Considered as key Strategies by Major players in Human Microbiome marketPR Newswire (press release) - Apr, 9 2018
Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in ...PR Newswire (press release) - Mar, 5 2018
Second Genome Appoints Matthew W. McClure, MD, as Chief Medical Officernanalyze - Mar, 3 2018
7 Startups Treating Disease Using the MicrobiomePR Newswire (press release) - Feb, 28 2018
Second Genome Strengthens R&D Program in Immuno-Oncology with Four Academic CollaborationsPR Newswire (press release) - Dec, 19 2017
Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After ...PR Newswire (press release) - Oct, 3 2017
Second Genome Launches Study of the Relationship Between Microbiome and Central Nervous System in Autism ...xconomy - Feb, 17 2017
FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugsxconomy - Jan, 9 2017
Digitalis Launches $100M Health Fund, With Emphasis On Dataprnewswire - Dec, 25 2016
Microbiome Therapeutics Market to Reach $433 Million by 2025 - Increasing Initiatives & Government Programs Driving Growth - Research and Marketsprnewswire - Dec, 9 2016
Second Genome Announces Appointments in Human Resources, Finance to Support Corporate Growthmedcitynews - Dec, 5 2016
Axial Biotherapeutics raises $19.15M to target gut-brain axisxconomy - Nov, 3 2016
With Bugs As Drugs, Evelo CEO Plans Immune, Cancer Trials in 2017xconomy - May, 3 2016
Probing Gut Microbiome, Second Genome Nabs $43M To Push Colitis Drugbusinesswire - May, 3 2016
Evotec to report First Quarter 2016 Results on 10 May 2016pehub - Apr, 24 2016
Second Genome raises $42.6 mln Series B roundmedcitynews - Apr, 24 2016
Pfizer, Roche join $42.6M round to fund microbiome player Second Genomeblogs - Apr, 23 2016
The Daily Startup: Second Genome Raises $42.6 Million to Pursue Microbiome-Based Therapiesprnewswire - Jan, 23 2016
Global Human Microbiome Market 2016-2023 - Key Players are Enterome Bioscience, Yakult, DuPont, Metabiomics & ViThera Pharmaceuticalsxconomy - Dec, 18 2015
New Speakers Join Gene-Edit, Microbiome, Big Data “Disruptors” 12/10xconomy - Dec, 18 2015
What Three Biotechs Could Tell Us About The Pfizer-Allergan Mergerxconomy - Dec, 17 2015
With Startup, Bio Pioneer Tom Maniatis Looks to Spark NY Scene Againxconomy - Nov, 4 2015
Xconomy’s EXOME Presents: Bay Area’s Life Science Disruptorsxconomy - Sep, 29 2015
Flagship Takes a Stab at Microbiome Therapy With Seres Healthwired - Sep, 29 2015
Data-Visualization Firm’s New Software Autonomously Finds Abstract Connectionsxconomy - Jun, 26 2015
On Eve of Seres IPO, A Rival Nonprofit Microbiome Treatment Expands | Xconomyxconomy - May, 22 2015
Second Genome Pockets $5M to Uncover the Secrets of Bugs, Good and Bad, in Your Gut | Xconomyxconomy - May, 22 2015
West Coast Biotech Roundup: Juno, Nektar, Kite, Glooko & More | Xconomyxconomy - May, 22 2015
Second Genome Has Begun First Drug Trial Based on Microbiome Secrets | Xconomyxconomy - May, 22 2015
Second Genome Gets J&J Deal, $6.5M, to Explore Bugs of the Gut | Xconomyxconomy - May, 22 2015
The Affymetrix Alumni: Where Are They Now? | Xconomywired - May, 21 2015
Data-Visualization Firm's New Software Autonomously Finds Abstract Connections | WIREDxconomy - May, 21 2015
Ginkgo Bioworks Grabs $9M Series A For Building Organisms | Xconomyfastcompany - May, 21 2015
What's Lurking In Your Microbiome? Possibly, a Cure for DiseaseEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
